Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 1
1966 1
1968 5
1970 4
1971 6
1972 1
1973 1
1974 4
1975 2
1976 1
1977 1
1978 8
1979 8
1980 2
1981 6
1982 10
1983 9
1984 10
1985 9
1986 21
1987 21
1988 8
1989 20
1990 14
1991 14
1992 13
1993 6
1994 14
1995 30
1996 20
1997 12
1998 13
1999 22
2000 11
2001 13
2002 13
2003 14
2004 10
2005 8
2006 5
2007 2
2011 1
2012 2
2013 1
2014 1
2015 3
2016 4
2017 4
2018 4
2019 4
2020 6
2021 14
2022 11
2023 12
2024 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

461 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial.
Colombo N, Biagioli E, Harano K, Galli F, Hudson E, Antill Y, Choi CH, Rabaglio M, Marmé F, Marth C, Parma G, Fariñas-Madrid L, Nishio S, Allan K, Lee YC, Piovano E, Pardo B, Nakagawa S, McQueen J, Zamagni C, Manso L, Takehara K, Tasca G, Ferrero A, Tognon G, Lissoni AA, Petrella M, Laudani ME, Rulli E, Uggeri S, Barretina Ginesta MP; AtTEnd study group. Colombo N, et al. Lancet Oncol. 2024 Sep;25(9):1135-1146. doi: 10.1016/S1470-2045(24)00334-6. Epub 2024 Aug 2. Lancet Oncol. 2024. PMID: 39102832 Clinical Trial.
Diagnostic Performance of Preoperative Imaging in Endometrial Cancer.
Hashimoto C, Shigeta S, Shimada M, Shibuya Y, Ishibashi M, Kageyama S, Sato T, Tokunaga H, Takase K, Yaegashi N. Hashimoto C, et al. Among authors: shigeta s. Curr Oncol. 2023 Sep 6;30(9):8233-8244. doi: 10.3390/curroncol30090597. Curr Oncol. 2023. PMID: 37754512 Free PMC article.
Human papillomavirus vaccine impact on invasive cervical cancer in Japan: Preliminary results from cancer statistics and the MINT study.
Onuki M, Takahashi F, Iwata T, Nakazawa H, Yahata H, Kanao H, Horie K, Konnai K, Nio A, Takehara K, Kamiura S, Tsuda N, Takei Y, Shigeta S, Matsumura N, Yoshida H, Motohara T, Yamazaki H, Nakamura K, Hamanishi J, Tasaka N, Ishikawa M, Hirashima Y, Kudaka W, Mori-Uchino M, Kukimoto I, Fujii T, Watanabe Y, Noda K, Yoshikawa H, Yaegashi N, Matsumoto K; MINT Study Group. Onuki M, et al. Among authors: shigeta s. Cancer Sci. 2023 Nov;114(11):4426-4432. doi: 10.1111/cas.15943. Epub 2023 Sep 8. Cancer Sci. 2023. PMID: 37688310 Free PMC article.
Current status of anti-SARS agents.
Shigeta S, Yamase T. Shigeta S, et al. Antivir Chem Chemother. 2005;16(1):23-31. doi: 10.1177/095632020501600103. Antivir Chem Chemother. 2005. PMID: 15739619 Free article. Review.
ExcLAMation marks in a pelvic lymph node.
Muroyama Y, Inoue C, Fujishima F, Shigeta S, Hasegawa-Minato J, Shimada M, Suzuki T. Muroyama Y, et al. Among authors: shigeta s. Clin Case Rep. 2023 Dec 14;11(12):e8339. doi: 10.1002/ccr3.8339. eCollection 2023 Dec. Clin Case Rep. 2023. PMID: 38098800 Free PMC article.
Identification of predictive biomarkers for endometrial cancer diagnosis and treatment response monitoring using plasma metabolome profiling.
Hishinuma E, Shimada M, Matsukawa N, Shima Y, Li B, Motoike IN, Shibuya Y, Hagihara T, Shigeta S, Tokunaga H, Saigusa D, Kinoshita K, Koshiba S, Yaegashi N. Hishinuma E, et al. Among authors: shigeta s. Cancer Metab. 2023 Oct 11;11(1):16. doi: 10.1186/s40170-023-00317-z. Cancer Metab. 2023. PMID: 37821929 Free PMC article.
461 results